Segmented Immunoconjugates for Tumor Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antigen-specific immunoconjugates face challenges such as inadequate uptake and poor distribution in tumors due to the large size of immunoglobulin molecules, leading to systemic toxicity and reduced effectiveness in cancer therapy, with a need for more specific and stable therapeutic agents.
Innovation Solution
Development of immunoconjugates comprising a first and second antigen binding moiety, such as Fv or Fab fragments, covalently linked through disulfide bonds with a cytokine effector moiety, designed to enhance specificity, stability, and reduced toxicity by targeting specific tumor sites.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If full-length immunoglobulin molecules are used as delivery agents, then tumor targeting capability is improved, but uptake and distribution in tumors deteriorates due to large molecule size
Solution Approach 1:
The patent applies segmentation by using immunoglobulin fragments (Fab, Fv, or scFv) instead of full-length immunoglobulin molecules. This divides the large immunoglobulin structure into smaller functional units that retain tumor targeting capability while improving uptake and distribution in tumors. The antigen binding moiety is segmented to maintain specificity while reducing size-related transport barriers.
Solution Approach 2:
The patent changes the size parameter of the delivery agent by transitioning from full-length immunoglobulins to fragments. This parameter change (reducing molecular size) directly addresses the uptake and distribution problem while the antigen binding capability is maintained through the preserved variable regions and binding sites in the fragmented structures.
2Reliability
If high doses of cytokine are administered systemically to achieve sufficient concentration at tumor site, then anti-tumor effect is improved, but toxicity and adverse reactions worsen
Solution Approach 1:
The cytokine is segmented and conjugated to the immunoglobulin fragment, creating a targeted immunoconjugate. This segmentation allows the cytokine to be delivered specifically to the tumor site rather than distributed systemically, achieving effective concentrations at the tumor while avoiding widespread toxicity.
Solution Approach 2:
The immunoglobulin fragment acts as an intermediary carrier that transports the cytokine from the circulation to the tumor site. This intermediary function enables localized delivery, allowing lower systemic doses of cytokine to achieve the same therapeutic effect at the tumor while reducing overall toxicity.
3Reliability
If immunoglobulin-cytokine fusion proteins are used to maximize immunostimulatory activities at tumor site, then therapeutic effectiveness is improved, but complexity of molecule structure worsens
Solution Approach 1:
The fusion protein structure is segmented into distinct functional modules: the immunoglobulin fragment (providing targeting) and the cytokine (providing immunostimulation). This modular segmentation makes the complex molecule more manageable for production and characterization, while each component maintains its specific function. The separation of functions into distinct segments simplifies the design compared to fully fused proteins.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The immunoconjugates demonstrate improved efficacy, specificity, and stability, allowing for localized biological effects and reduced toxicity, effectively inhibiting tumor growth and prolonging survival in mammals with malignant tumors.
Implementation Method 1
comprising a first and second antigen binding moiety, such as Fv or Fab fragments, covalently linked through disulfide bonds with a cytokine effector moiety
Data Source
AI summary
The present invention relates to immunoconjugates. In particular embodiments, the present invention relates to immunoconjugates comprising at least one single-chain effector moiety and two or more antigen binding moieties. In addition, the present invention relates to nucleic acid molecules encoding such immunoconjugates, vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the immunoconjugates of the invention, and to methods of using these immunoconjugates in the treatment of disease.